Results 151 to 160 of about 3,331 (189)

Estetrol/Drospirenone safety in a population with cardiovascular risk factors [PDF]

Contraception
ObjectivesTo evaluate cardiovascular safety outcomes in estetrol 15mg/drospirenone 3mg users with cardiovascular risk factors.Study designWe performed a secondary analysis of two open-label contraceptive phase-3 trials that enrolled participants 16 to 50
Mitchell Creinin, Kristina Gemzell-Danielsson, Archie Kubba   +2 more
exaly   +2 more sources

Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone

European Journal of Contraception and Reproductive Health Care, 2000
peer reviewedTo assess the contraceptive reliability, cycle control and tolerability of a new monophasic oral contraceptive containing 30 g ethinylestradiol plus 3 mg drospirenone (Yasmin, Schering AG, Berlin, Germany), it was compared with an ...
Jean-Michel Foidart, R Heithecker
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Drospirenone/ethinylestradiol

Reactions Weekly, 2023
openaire   +2 more sources

Drospirenone/ethinylestradiol

Reactions Weekly, 2021
openaire   +2 more sources

Ethinylestradiol/drospirenone

Reactions Weekly, 2015
  +5 more sources

Drospirenone

Drugs of the Future, 2000
null Norman, P., null Castaner, J., null Castaner, R.M.   +2 more
openaire   +1 more source

Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone

Contraception, 2021
Jean-Michel Foidart, Christine Klipping, Íngrid Duijkers   +2 more
exaly  

Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function

Contraception, 2021
Jean-Michel Foidart, Christine Klipping, Íngrid Duijkers   +2 more
exaly  

Drospirenone/ethinylestradiol

Reactions Weekly
  +6 more sources

Drospirenone

Reactions Weekly, 2016
openaire   +1 more source